DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR-928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT’s Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. Human applications may include acute organ injury, chronic metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and other liver disorders. DURECT’s advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (SABER®-Bupivacaine), an investigational non-opioid analgesic intended to address key unmet needs in postoperative pain management. Another is REMOXY® ER (oxycodone), based on DURECT’s ORADUR® technology, an investigational extended-release pain reliever that has been out-licensed to Pain Therapeutics, Inc. Opioid medications such as oxycodone expose users to risks of addiction, misuse, and abuse.

Stock Quote
NASDAQ DRRX (Common Stock)
Oct 22, 2018 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent News | View All >
DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer

Read More

DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference

Read More

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever DURECT Corporation posts new information to the site. Just enter your e-mail address and click Submit.
Transfer Agent
Computershare Trust Company N.A.
250 Royall Street, Mailstop 3B
Canton, MA 02021
Phone: 781-575-3400

Ernst & Young LLP
560 Mission Street, Suite 1600
San Francisco, CA 94105-2907
Phone: 415 894 8000
Fax: 415 894 8099